Have had weight loss surgery
Here's the distinction: What the FDA targeted: 503A and 503B compounding pharmacies producing peptide formulations marketed as treatments particularly compounded versions of FDA-approved GLP-1 agonists (semaglutide, tirzepatide) during drug shortage periods What the FDA did NOT target: Research chemical vendors selling peptides under the "for research use only" framework without therapeutic claims The key variable: Marketing claims
While IGF 1 will virtually act on all of the bodys cells, looking at what it can do in muscle cells, it will boost protein synthesis, it might act as a glucose uptake aid , and it will also lead to a positive Nitrogen balance [2, 3]
Maximum benefits develop over 3-6 months
The determinants of functional and regulatory changes in GGT and ChaC1/ChaC2 across different malignancies or settings remain elusive
adems, algunos combinan nutrientes anablicos, introduciendo sesgo de confusin